News Search Results
Mar 10, 2026, 08:37 ET QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman
for agency approval." The therapy at issue is uniQure's lead gene therapy candidate, AMT-130, which is being developed to slow the progression of Huntington's disease.Worse, the WSJ reported "[t]he official also said a Uniqure executive had mischaracterized the FDA's request for how to compare
More news about: Hagens Berman Sobol Shapiro LLP
Mar 10, 2026, 03:42 ET Neurodegenerative Disease Devices Market to Witness Steady Growth Through 2032, Driven by Advanced Neuromodulation, Says Vyansa Intelligence
Rehabilitation DevicesBy Indication: Parkinsons Disease, Alzheimers Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntingtons Disease, Epilepsy, Stroke, and OthersBy Technology Platform: Implantable Devices, External / Non-Invasive Devices, Wearable &
More news about: Vyansa Intelligence
Mar 07, 2026, 11:45 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 06, 2026, 09:05 ET Huntington Bancshares Incorporated to Present at the 2026 RBC Capital Markets Global Financial Institutions Conference
Webcast InformationInterested investors may access the live audio webcast in the investor relations section of Huntington's website (
More news about: Huntington Bancshares Incorporated
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Mar 05, 2026, 02:25 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Mar 03, 2026, 13:00 ET Huntington Bank and Broadstreet launch $25M NMTC fund to fuel economic opportunity in low-income communities
trained healthcare workers, as well as the aspirations of individuals working to increase their skills, opportunities and incomes. In addition to Huntington's investment through the fund, the Local Initiatives Support Corporation (LISC) provided NMTCs to lower the cost of capital for the development, as
More news about: Broadstreet Impact Services
Mar 03, 2026, 09:04 ET CenExel Clinical Research Network Expands Capabilities Across Sites Nationwide
square feet of space with an additional 11 inpatient rooms to focus on indications in the neurodegenerative space, including Alzheimer's disease, Huntington's disease and Parkinson's disease.Anaheim, CaliforniaIn mid-2025, CenExel Anaheim completed an 8,000-square-foot expansion and
More news about: CenExel Clinical Research
Mar 02, 2026, 16:19 ET Skyhawk gibt bekannt, dass die australische Arzneimittelbehörde festgestellt hat, dass SKY-0515 zur Behandlung der Huntington-Krankheit die Zulassungskriterien für den vorläufigen Zulassungsweg erfüllt
https://www.aihw.gov.au/reports/neurological-conditions/huntingtons-disease-in-australiaHuntington's Disease Society of America (HDSA) 2026, Überblick über die Huntington-Krankheit, abgerufen
More news about: Skyhawk Therapeutics
Mar 02, 2026, 11:45 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 02, 2026, 11:25 ET Huntington Bank Opens Flagship Branch in Winston-Salem
New location builds on Huntington's growing presence in the CarolinasWINSTON-SALEM, N.C. , March 2, 2026 /PRNewswire/ -- The Huntington National Bank (Huntington) today announced the opening of
More news about: Huntington Bank
Mar 02, 2026, 10:31 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
https://www.aihw.gov.au/reports/neurological-conditions/huntingtons-disease-in-australiaHuntington's Disease Society of America (HDSA) 2026, Overview of Huntington's Disease, viewed 8 February 2026,
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:22 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
https://www.aihw.gov.au/reports/neurological-conditions/huntingtons-disease-in-australiaHuntington's Disease Society of America (HDSA) 2026, Overview of Huntington's Disease, viewed 8 February 2026,
More news about: Skyhawk Therapeutics
Feb 27, 2026, 16:48 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P. A.
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds
More news about: Neurocrine Biosciences, Inc.
Feb 24, 2026, 13:00 ET Walter Koroshetz Joins the Dana Foundation as Senior Advisor
at Harvard Medical School and led neurology resident training at MGH between 1990 and 2007. His early research in the lab and clinic focused on Huntington's disease, and with the team at MGH performed the first study of pre-symptomatic testing.The
More news about: Dana Foundation
Feb 23, 2026, 11:00 ET Limb Prosthetics Market to Reach $2.9 Billion, Globally, by 2033 at 5.6% CAGR: Allied Market Research
2031Huntington's Disease Treatment Market: Global Opportunity Analysis and Industry Forecast, 2021 - 2031
More news about: Allied Market Research
Feb 23, 2026, 09:36 ET NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
headquartered in Amsterdam, the Netherlands, is a biotechnology company focused on the development of gene therapies for severe diseases, including Huntington's disease (HD).The Complaint alleges that during the Class Period, Defendants misrepresented and/or failed to disclose that: (1)
More news about: Berger Montague
Feb 23, 2026, 01:00 ET QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food
More news about: THE ROSEN LAW FIRM, P.A.
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees
More news about: Pomerantz LLP
Feb 19, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
milestone from Roche based on single-year Evrysdi sales of $2.5 billionEnd-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington's disease (HD) programAlignment reached on design of global Phase 3 trial, INVEST-HD, which is planned to initiate in 1H 2026FDA
More news about: PTC Therapeutics, Inc.
Feb 18, 2026, 20:47 ET NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.
Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 18, 2026, 02:49 ET BioArctic Interim Report for the period October - December 2025
strengthening our pipeline to take the next step as a company. Since then, we have strengthened our project portfolio with two new projects, one in Huntington's disease and one related to Parkinson´s disease, as well as advanced our existing projects.In the fourth quarter, we also nominated candidate
More news about: BioArctic